Health
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data
HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the reconstitution of its Scientific Advisory Board (SAB) with the appointment of three renowned experts in neurology, neuroimaging, and neurodegenerative diseases. This move reflects Nexalin’s strategic prioritization of Alzheimer’s disease within its broader clinical development pipel
About this update from Nexalin Technology, Inc.
[{"type":"image","alt":"Nexalin Technology, Inc.","displaySize":"","headline":null,"caption":"Nexalin Technology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":200,"url":"https://media.zenfs.com/en/globenewswire.com/5068cf7d0dc54dda72cad25cf178ec76"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kPm7LNc3A4iAJ.KL_fneQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5068cf7d0dc54dda72cad25cf178ec76","width":200,"height":200}},"lazy":false},{"type":"text","content":"HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the reconstitution of its Scientific Advisory Board (SAB) with the appointment of three renowned experts in neurology, neuroimaging, and neurodegenerative diseases. This move reflects Nexalin’s strategic prioritization of Alzheimer’s disease within its broader clinical development pipeline, supported by promising published data and internal data from studies involving its proprietary DIFS™ technology.","length":617,"tagName":"p"},{"type":"text","content":"Joining the SAB are Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer, each of whom brings specialized expertise that aligns with Nexalin’s Alzheimer’s-focused initiatives. The restructured SAB will play a pivotal role in guiding the Company’s scientific direction, clinical strategy, and biomarker-driven trial design for neurodegenerative and neuropsychiatric disorders.","length":379,"tagName":"p"},{"type":"text","content":"“This enhanced advisory board reflects our sharpened focus on Alzheimer’s disease, and the high-caliber expertise of Drs. Huang, Owens, and Scheer aligns with our expanding research agenda,” said Mark White, CEO of Nexalin Technology. “Their combined contributions will be invaluable as we advance Nexalin’s technology through clinical trials designed to address one of the greatest public health challenges of our time.”","length":421,"tagName":"p"},{"type":"text","content":"Nexalin’s Gen-2 SYNC and Gen-3 Halo™ headset delivers DIFS™, a proprietary waveform capable of penetrating deep brain structures implicated in cognitive decline and mental illness. Recent published articles and encouraging preclinical and early-...